Print

IPCAVD010

A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140

Trial Details:

I Ongoing
Crucell Holland BV March 01, 2016
Ad26.Mos.HIV Trivalent,gp140 C Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Clade C gp140
Ad26.Mos.HIV Trivalent Viral Vector - Adeno
gp140 C Protein
USA 36
NCT02685020
https://www.clinicaltrials.gov/ct2/show/NCT02685020?term=NCT02685020&rank=1